* Astrana Health Inc ASTH.OQ ASTH.O is expected to show
a rise
in quarterly revenue when it reports results on May 7 for the
period ending March 31 2024
* The Alhambra California-based company is expected to
report a
22.7% increase in revenue to $413.849 million from $337.24
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Astrana Health Inc is
for
earnings of 30 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 3.3%
in the last three months.
* Wall Street's median 12-month price target for Astrana
Health
Inc is $50.00, above its last closing price of $37.46.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.15 0.15 0.26 Beat 75.3
Sep. 30 2023 0.31 0.33 0.47 Beat 42.4
Jun. 30 2023 0.25 0.25 0.28 Beat 12
Mar. 31 2023 0.31 0.31 0.31 Met 1.1
Dec. -0.11 -0.09 -0.06 Beat 33.3
31 2022
Sep. 30 2022 0.31 0.32 0.56 Beat 75.8
Jun. 30 2022 0.20 0.20 0.25 Beat 23.2
Mar. 31 2022 0.32 0.32 0.31 Missed -3.1
This summary was machine generated May 4 at 02:11 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)